Sana Biotechnology (NASDAQ:SANA) Coverage Initiated at Rodman & Renshaw

Rodman & Renshaw started coverage on shares of Sana Biotechnology (NASDAQ:SANA) in a research report sent to investors on Wednesday morning, Marketbeat reports. The brokerage issued a buy rating and a $16.00 price objective on the stock.

Other equities analysts have also issued reports about the stock. JMP Securities upped their price target on shares of Sana Biotechnology from $8.00 to $15.00 and gave the stock a market outperform rating in a research report on Friday, March 1st. HC Wainwright reiterated a buy rating and issued a $12.00 price target on shares of Sana Biotechnology in a research report on Thursday, May 9th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of Moderate Buy and a consensus price target of $12.75.

Sana Biotechnology Stock Up 1.1 %

Shares of SANA stock opened at $5.46 on Wednesday. The company has a 50 day moving average price of $7.68 and a 200-day moving average price of $7.38. Sana Biotechnology has a 52 week low of $2.74 and a 52 week high of $12.00. The firm has a market capitalization of $1.21 billion, a PE ratio of -3.57 and a beta of 1.53.

Sana Biotechnology (NASDAQ:SANA) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.02). Analysts anticipate that Sana Biotechnology will post -1.15 earnings per share for the current year.

Institutional Investors Weigh In On Sana Biotechnology

Hedge funds have recently bought and sold shares of the business. Victory Capital Management Inc. purchased a new stake in Sana Biotechnology during the fourth quarter valued at $54,000. Hartline Investment Corp purchased a new stake in shares of Sana Biotechnology in the first quarter valued at $136,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Sana Biotechnology by 42.1% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,257 shares of the company’s stock valued at $66,000 after acquiring an additional 4,815 shares during the period. Simplex Trading LLC raised its stake in shares of Sana Biotechnology by 31.3% in the fourth quarter. Simplex Trading LLC now owns 18,080 shares of the company’s stock valued at $73,000 after acquiring an additional 4,313 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its stake in shares of Sana Biotechnology by 351.8% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 22,800 shares of the company’s stock valued at $93,000 after acquiring an additional 17,753 shares during the period. Hedge funds and other institutional investors own 88.23% of the company’s stock.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.